Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Sr. VP of Bus. Development | January 03, 2017 | January 05, 2017 |
| Marker Therapeutics, Inc.MRKR · Entity 7609 | Director · President and CEO | March 24, 2022 | March 29, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2017 · Filed January 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2027-01-02 | Direct | 11,250 |
Reported balance
After 2017-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-03 · Grant · Acquired 11,250 · Balance 11,250 F1: 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,250 |
Reported balance
After 2017-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-03 · Grant · Acquired 6,250 · Balance 6,250 F2: Each restricted stock unit represents a contingent right to receive one share of BLCM common stock. F3: The restricted stock units vest in four equal annual installments beginning January 3, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of BLCM common stock.
F3: The restricted stock units vest in four equal annual installments beginning January 3, 2018.
Marker Therapeutics, Inc.
Report date March 24, 2022 · Filed March 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 483,286 |
Ending reported balance
After 2022-03-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-24 · Grant · Acquired 199,094 · Balance 531,662 F1: Represents a restricted stock unit ("RSU") award. Row 2 · 2022-03-24 · Tax withholding · Disposed 48,376 · Balance 483,286 F2: Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award.
F2: Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2022 Filed Mar 29, 2022 01:06 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | Tax withholdingCommon Stock | 48,376 | $0.48 | $23,452.68 |
DisclosureSEC source: 0001209191-22-021396 · doc4.xml · nonDerivative · entry 2 Hoang Peter L. · CIK 0001626893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,286 F2 · shares: Represents shares withheld to satisfy tax obligations with respect to the vesting of the RSUs. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 01:06 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantCommon Stock | 199,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021396 · doc4.xml · nonDerivative · entry 1 Hoang Peter L. · CIK 0001626893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,662 F1 · shares: Represents a restricted stock unit ("RSU") award. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:14 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 430,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001209191-22-011791 · doc4.xml · derivative · entry 1 Hoang Peter L. · CIK 0001626893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,000 Underlying: Common Stock · 430,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:36 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | PurchaseCommon Stock | 142,857 | $1.75 | $249,999.75 |
DisclosureSEC source: 0001209191-21-021771 · doc4.xml · nonDerivative · entry 1 Hoang Peter L. · CIK 0001626893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,568 Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 22:26 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (right to buy) · Derivative | 430,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-21-010267 · doc4.xml · derivative · entry 1 Hoang Peter L. · CIK 0001626893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,000 Underlying: Common Stock · 430,000 shares Expires 2031-02-11 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 11, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:46 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 388,800 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-018556 · doc4.xml · derivative · entry 2 Hoang Peter L. · CIK 0001626893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,800 Underlying: Common Stock · 388,800 shares Expires 2030-03-10 F2 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:46 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-018556 · doc4.xml · derivative · entry 1 Hoang Peter L. · CIK 0001626893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2030-03-10 F1 · derivative.exercise_date: Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 20:33 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | PurchaseCommon Stock | 10,000 | $4.62 | $46,200.00 |
DisclosureSEC source: 0001209191-19-046149 · doc4.xml · nonDerivative · entry 1 Hoang Peter L. · CIK 0001626893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,711 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.55 to $4.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 21:10 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001144204-18-054994 · tv505273_form4.xml · derivative · entry 2 Hoang Peter L. · CIK 0001626893 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-10-19 F2 · security: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended to Tsvetelina Hoang, Mr. Hoang's wife who serves as the Company's Vice President, Research and Development. One fifth of the shares vest ten months after the grant date, the remainder of the shares vest in monthly installments thereafter upon the continued employment of Dr. Hoang by the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018. F2 · derivative.exercise_date: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended to Tsvetelina Hoang, Mr. Hoang's wife who serves as the Company's Vice President, Research and Development. One fifth of the shares vest ten months after the grant date, the remainder of the shares vest in monthly installments thereafter upon the continued employment of Dr. Hoang by the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 21:10 UTC | Marker Therapeutics, Inc. MRKR · Entity 7609 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,359,855 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001144204-18-054994 · tv505273_form4.xml · derivative · entry 1 Hoang Peter L. · CIK 0001626893 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,359,855 Underlying: Common Stock · 1,359,855 shares Expires 2028-10-19 F1 · security: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended. These options vest and are exercisable immediately. The option exercise price is the closing price on the date of the grant, October 19, 2018. F1 · derivative.exercise_date: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended. These options vest and are exercisable immediately. The option exercise price is the closing price on the date of the grant, October 19, 2018. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 19:11 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | Tax withholdingCommon Stock | 70,289 | $3.18 | $223,519.02 |
DisclosureSEC source: 0001144204-17-049443 · v475755_4.xml · nonDerivative · entry 2 Hoang Peter L. · CIK 0001626893 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,711 F2 · shares: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the restricted stock award. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 19:11 UTC | Marker Therapeutics, Inc. TPIV · Entity 7609 | GrantCommon Stock | 250,000 | $3.18 | $795,000.00 |
DisclosureSEC source: 0001144204-17-049443 · v475755_4.xml · nonDerivative · entry 1 Hoang Peter L. · CIK 0001626893 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 F1 · shares: Represents shares of fully vested restricted stock issued under the Company's 2014 Omnibus Stock Ownership Plan in connection with initial employment as President and Chief Executive Officer and the execution of employment agreement. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:18 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001358403-17-000019 · wf-form4_148366186920859.xml · derivative · entry 2 Hoang Peter L. · CIK 0001626893 · Sr. VP of Bus. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of BLCM common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 3, 2018. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:18 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantEmployee Stock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $13.89 | $0.00 |
DisclosureSEC source: 0001358403-17-000019 · wf-form4_148366186920859.xml · derivative · entry 1 Hoang Peter L. · CIK 0001626893 · Sr. VP of Bus. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.